Splice variants of mda-7/IL-24 differentially affect survival and induce apoptosis in U2OS cells

Cytokine

Volumn 56, Issue 2, 2011, Pages 272-281

  Whitaker, Erin L ^a   Filippov, Valery ^a   Filippova, Maria ^a   Guerrero Juarez, Christian F ^a   Duerksen Hughes, Penelope J ^a  

^a LOMA LINDA UNIVERSITY   (United States)

Author keywords

Alternative splicing; Apoptosis; IL 24; Mda 7; SRp55

Indexed keywords

CASPASE 3; CASPASE 7; INTERLEUKIN 24;

ALTERNATIVE RNA SPLICING; AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; CELL LINE; CELL STRAIN NOK; CELL STRAIN U2OS; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; EXON; HUMAN; HUMAN CELL; MOLECULAR CLONING; MUTAGENESIS; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

AMINO ACID SEQUENCE; APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; DNA PRIMERS; HUMANS; INTERLEUKINS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; RNA SPLICING; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 80053311326     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.07.020     Document Type: Article

References (48)

1. Johnson J.M., Castle J., Garrett-Engele P., Kan Z., Loerch P.M., Armour C.D., et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 2003, 302:2141-2144.
2. Brinkman B.M. Splice variants as cancer biomarkers. Clin Biochem 2004, 37:584-594.
3. Skotheim R.I., Nees M. Alternative splicing in cancer: noise, functional, or systematic?. Int J Biochem Cell Biol 2007, 39:1432-1449.
4. Venables J.P. Aberrant and alternative splicing in cancer. Cancer Res 2004, 64:7647-7654.
5. Wang Z., Lo H.S., Yang H., Gere S., Hu Y., Buetow K.H., et al. Computational analysis and experimental validation of tumor-associated alternative RNA splicing in human cancer. Cancer Res 2003, 63:655-657.
6. Black D.L. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 2003, 72:291-336.
7. Graveley B.R. Sorting out the complexity of SR protein functions. RNA 2000, 6:1197-1211.
8. Krecic A.M., Swanson M.S. HnRNP complexes: composition, structure, and function. Curr Opin Cell Biol 1999, 11:363-371.
9. Stamm S., Ben-Ari S., Rafalska I., Tang Y., Zhang Z., Toiber D., et al. Function of alternative splicing. Gene 2005, 344:1-20.
10. Stamm S. Signals and their transduction pathways regulating alternative splicing: a new dimension of the human genome. Hum Mol Genet 2002, 11:2409-2416.
11. Caudell E.G., Mumm J.B., Poindexter N., Ekmekcioglu S., Mhashilkar A.M., Yang X.H., et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol 2002, 168:6041-6046.
12. Jiang H., Lin J.J., Su Z.Z., Goldstein N.I., Fisher P.B. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 1995, 11:2477-2486.
13. Ellerhorst J.A., Prieto V.G., Ekmekcioglu S., Broemeling L., Yekell S., Chada S., et al. Loss of MDA-7 expression with progression of melanoma. J Clin Oncol 2002, 20:1069-1074.
14. Saeki T., Mhashilkar A., Chada S., Branch C., Roth J.A., Ramesh R. Tumor-suppressive effects by adenovirus-mediated mda-7 gene transfer in non-small cell lung cancer cell in vitro. Gene Ther 2000, 7:2051-2057.
15. Lebedeva I.V., Sarkar D., Su Z.Z., Kitada S., Dent P., Stein C.A., et al. Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene 2003, 22:8758-8773.
16. Lebedeva I.V., Sauane M., Gopalkrishnan R.V., Sarkar D., Su Z.Z., Gupta P., et al. Mda-7/IL-24: exploiting cancer's Achilles' heel. Mol Ther 2005, 11:4-18.
17. Lebedeva I.V., Su Z.Z., Sarkar D., Gopalkrishnan R.V., Waxman S., Yacoub A., et al. Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis. Oncogene 2005, 24:585-596.
18. Mhashilkar A.M., Schrock R.D., Hindi M., Liao J., Sieger K., Kourouma F., et al. Melanoma differentiation associated gene-7 (mda-7): a novel anti-tumor gene for cancer gene therapy. Mol Med 2001, 7:271-282.
19. Su Z.Z., Lebedeva I.V., Sarkar D., Gopalkrishnan R.V., Sauane M., Sigmon C., et al. Melanoma differentiation associated gene-7, mda-7/IL-24, selectively induces growth suppression, apoptosis and radiosensitization in malignant gliomas in a p53-independent manner. Oncogene 2003, 22:1164-1180.
20. Chen W.Y., Cheng Y.T., Lei H.Y., Chang C.P., Wang C.W., Chang M.S. IL-24 inhibits the growth of hepatoma cells in vivo. Genes Immun 2005, 6:493-499.
21. Leath C.A., Kataram M., Bhagavatula P., Gopalkrishnan R.V., Dent P., Fisher P.B., et al. Infectivity enhanced adenoviral-mediated mda-7/IL-24 gene therapy for ovarian carcinoma. Gynecol Oncol 2004, 94:352-362.
22. Lebedeva I.V., Su Z.Z., Chang Y., Kitada S., Reed J.C., Fisher P.B. The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells. Oncogene 2002, 21:708-718.
23. Su Z.Z., Madireddi M.T., Lin J.J., Young C.S., Kitada S., Reed J.C., et al. The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. Proc Natl Acad Sci USA 1998, 95:14400-14405.
24. Yacoub A., Mitchell C., Brannon J., Rosenberg E., Qiao L., McKinstry R., et al. MDA-7 (interleukin-24) inhibits the proliferation of renal carcinoma cells and interacts with free radicals to promote cell death and loss of reproductive capacity. Mol Cancer Ther 2003, 2:623-632.
25. Lebedeva I.V., Emdad L., Su Z.Z., Gupta P., Sauane M., Sarkar D., et al. Mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Int J Oncol 2007, 31:985-1007.
26. Su Z., Emdad L., Sauane M., Lebedeva I.V., Sarkar D., Gupta P., et al. Unique aspects of mda-7/IL-24 antitumor bystander activity: establishing a role for secretion of MDA-7/IL-24 protein by normal cells. Oncogene 2005, 24:7552-7566.
27. Cunningham C.C., Chada S., Merritt J.A., Tong A., Senzer N., Zhang Y., et al. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol Ther 2005, 11:149-159.
28. Tong A.W., Nemunaitis J., Su D., Zhang Y., Cunningham C., Senzer N., et al. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther 2005, 11:160-172.
29. Chada S., Mhashilkar A.M., Ramesh R., Mumm J.B., Sutton R.B., Bocangel D., et al. Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism. Mol Ther 2004, 10:1085-1095.
30. Gopalkrishnan R.V., Sauane M., Fisher P.B. Cytokine and tumor cell apoptosis inducing activity of mda-7/IL-24. Int Immunopharmacol 2004, 4:635-647.
31. Sauane M., Gopalkrishnan R.V., Choo H.T., Gupta P., Lebedeva I.V., Yacoub A., et al. Mechanistic aspects of mda-7/IL-24 cancer cell selectivity analysed via a bacterial fusion protein. Oncogene 2004, 23:7679-7690.
32. Parrish-Novak J., Xu W., Brender T., Yao L., Jones C., West J., et al. Interleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor-ligand interactions mediate unique biological functions. J Biol Chem 2002, 277:47517-47523.
33. Chada S., Bocangel D., Ramesh R., Grimm E.A., Mumm J.B., Mhashilkar A.M., et al. Mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer. Mol Ther 2005, 11:724-733.
34. Zheng M., Bocangel D., Doneske B., Mhashilkar A., Ramesh R., Hunt K.K., et al. Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10. Cancer Immunol Immunother 2007, 56:205-215.
35. Kreis S., Philippidou D., Margue C., Rolvering C., Haan C., Dumoutier L., et al. PLoS ONE 2007, 2:e1300.
36. Huang E.Y., Madireddi M.T., Gopalkrishnan R.V., Leszczyniecka M., Su Z., Lebedeva I.V., et al. Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene 2001, 20:7051-7063.
37. Allen M., Pratscher B., Roka F., Krepler C., Wacheck V., Schöfer C., et al. Loss of novel mda-7 splice variant (mda-7s) expression is associated with metastatic melanoma. J Invest Dermatol 2004, 123:583-588.
38. Allen M., Pratscher B., Krepler C., Frei K., Schöfer C., Pehamberger H., et al. Alternative splicing of IL-24 in melanocytes by deletion of exons 3 and 5. Int J Immunogenet 2005, 32:375-378.
39. Sahoo A., Jung Y.M., Kwon H.K., Yi H.J., Lee S., Chang S., et al. A novel splicing variant of mouse interleukin (IL)-24 antagonizes IL-24-induced apoptosis. J Biol Chem 2008, 283:28860-28872.
40. Alms W.J., Atamas S.P., Yurovsky V.V., White B. Generation of a variant of human interleukin-4 by alternative splicing. Mol Immunol 1996, 33:361-370.
41. Bihl M.P., Heinimann K., Rüdiger J.J., Eickelberg O., Perruchoud A.P., Tamm M., et al. Identification of a novel IL-6 isoform binding to the endogenous IL-6 receptor. Am J Respir Cell Mol Biol 2002, 27:48-56.
42. Korte A., Möricke A., Beyermann B., Köchling J., Taube T., Kebelmann-Betzing C., et al. Extensive alternative splicing of interleukin-7 in malignant hematopoietic cells: implication of distinct isoforms in modulating IL-7 activity. J Interferon Cytokine Res 1999, 19:495-503.
43. Rahman M., Nara H., Onoda T., Araki A., Li J., Hoshino T., et al. Cloning and characterization of an isoform of interleukin-21. FEBS Lett 2007, 581:4001-4009.
44. Tsytsikov V.N., Yurovsky V.V., Atamas S.P., Alms W.J., White B. Identification and characterization of two alternative splice variants of human interleukin-2. J Biol Chem 1996, 271:23055-23060.
45. Wu S., Gessner R., Taube T., von Stackelberg A., Henze G., Seeger K. Expression of interleukin-10 splicing variants is a positive prognostic feature in relapsed childhood acute lymphoblastic leukemia. J Clin Oncol 2005, 23:3038-3042.
46. Filippov V., Schmidt E.L., Filippova M., Duerksen-Hughes P.J. Splicing and splice factor SRp55 participate in the response to DNA damage by changing isoform ratios of target genes. Gene 2008, 420:34-41.
47. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282:1497-1501.
48. Piboonniyom S.O., Duensing S., Swilling N.W., Hasskarl J., Hinds P.W., Münger K. Abrogation of the retinoblastoma tumor suppressor checkpoint during keratinocyte immortalization is not sufficient for induction of centrosome-mediated genomic instability. Cancer Res 2003, 63:476-483.